About UsProductsPipelineNewsInvestor RelationsCustomer ServiceCareers
Investor Relations

Corporate Profile

Press Releases

SEC Filings

Calendar of Events

Information Requests

E-mail Alerts

IR Contact

FAQ

Site Map






Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Printer Friendly Version View printer-friendly version
<< Back
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time

N. Billerica, Mass., November 6, 2013 – Lantheus Medical Imaging, Inc. ("Lantheus") today announced that it will host a conference call at 3:00 p.m. ET on Wednesday, November 13, 2013, to discuss its financial and operating results for the third quarter of 2013.

To access the live conference call via telephone, please dial 1-877-280-4957 (U.S. callers) or 1 857-244-7314 (international callers) and provide passcode 97560845. A live audio webcast of the call also will be available on the homepage of the Company's website at www.lantheus.com.

A replay of the telephone conference call and audio webcast will be available from approximately 7:00 p.m. ET on November 13, 2013 through midnight on November 27, 2013. To access a replay of the conference call, dial 1-888-286-8010 (U.S. callers) or 1-617-801-6888 (international callers), and provide passcode 83049925.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company's proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 550 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

CONTACTS:
Linda Lennox
978-671-8854

Meara Murphy
978-671-8508


© 2013 Lantheus Medical Imaging, Inc.